Executive Summary & TL;DR
Headline Performance & Beat/Miss Callout
Eli Lilly and Company reported outstanding Q3 2026 financial results, significantly beating market expectations across top-line and bottom-line metrics:
- Revenue: $24,396.8 million (+38.6% YoY) vs. pre-release consensus estimate of $22,500.0 – $22,610.0 million (Beat by ~$1.84B / 8.2%).
- GAAP Diluted EPS: $7.22 (+16.3% YoY) vs. consensus estimate of $5.70 (Beat by $1.52).
- Non-GAAP Diluted EPS: $7.48 (+6.6% YoY) vs. consensus range of $6.61 – $7.03 (Beat by $0.66 at midpoint).
Guidance Direction
- Guidance Raised: Management raised full-year 2026 revenue guidance to $91.0B – $92.0B (up $5.5B–$6.0B from the prior range of $85.0B – $87.0B). Full-year 2026 Non-GAAP Diluted EPS guidance was updated to $35.00 – $36.00 (from $35.50 – $36.50 prior), incorporating heavy quarterly acquired IPR&D charges.
Key Takeaways
- Incretin Portfolio Dominance: Combined revenue from tirzepatide products (Mounjaro at $6,521.0 million, +109.5% YoY, and Zepbound at $3,568.0 million, +183.7% YoY) exceeded $10.08 billion in Q3, demonstrating robust global demand.
- Volume Growth Outpaces Price Erosion: Worldwide tirzepatide volume grew +53% YoY. Volume gains easily absorbed realized price declines caused by international reimbursement entries (e.g., China NRDL) and US Most Favored Nation (MFN) cash-pay pricing adjustments.
- Acquired IPR&D Dilution: Q3 GAAP and Non-GAAP earnings were burdened by $4,183.0 million ($4.57 per share) in acquired IPR&D charges, primarily tied to the acquisitions of AtaiBeckley, Inc. and Curevo, compared to $638.1 million ($0.71 per share) in Q3 2025.
- Expanding Commercial Footprint: The third quarter marked the first full quarter post-launch contribution from oral GLP-1 Foundayo (orforglipron) following its April FDA approval, broadening Lilly's metabolic franchise beyond injectables.